Bcl2相关髓细胞白血病序列1(MCL1)多克隆抗体
Polyclonal Antibody to Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1)
EAT; MCL1L; MCL1S; BCL2L3; TM; Myeloid Cell Leukemia Sequence 1, Bcl2 Related; Bcl-2-like protein 3; Bcl-2-related protein EAT/mcl1; mcl1/EAT
- 编号PAC615Mu01
- 物种Mus musculus (Mouse,小鼠) 相同的名称,不同的物种。
- 来源多抗制备
- 宿主兔
- 效价-
- Ig类型 IgG
- 纯化方式抗原特异性亲和纯化
- 标记物无标记物
- 免疫原 RPC615Mu01-Bcl2相关髓细胞白血病序列1(MCL1)重组蛋白
- 缓冲液成份磷酸盐缓冲液(pH7.4,含有0.02% NaN3和50%甘油)
- 性状液体
- 浓度0.5mg/mL
- 且适物种Homo sapiens (Human,人)
- 应用WB; IHC; ICC/IF;FCM
如果抗体需用于流式细胞术,请参见流式抗体。 - 下载 英文说明书 中文说明书
- 规格 20µl100µl 200µl 1ml 10ml
- 价格 ¥ 648 ¥ 1512 ¥ 2160 ¥ 5400 ¥ 21600
- 欲了解实际交易价格和更多情况,请与当地经销商联系!
特异性
该抗体是针对MCL1的兔多克隆抗体。在免疫组织化学染色和免疫印迹实验中能识别MCL1。
用法
Western blotting: 0.01-2μg/mL;
Immunohistochemistry: 5-20μg/mL;
Immunocytochemistry: 5-40μg/mL;
Flow cytometry:20μg/ml;
Optimal working dilutions must be determined by end user.
储存
经常使用则4°C保存。-20°C保存不超过两年。避免反复冻融。
稳定性
热稳定性以损失率显示。损失率是由加速降解试验决定,具体方法如下:在37°C孵育48小时,没有显著的降解或者沉淀产生。保质期内,在适当的条件下存储,损失率低于5%。
赠品
增值服务
相关产品
编号 | 适用物种:Mus musculus (Mouse,小鼠) | 应用(仅供研究使用,不用于临床诊断!) |
RPC615Mu01 | Bcl2相关髓细胞白血病序列1(MCL1)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPC615Mu02 | Bcl2相关髓细胞白血病序列1(MCL1)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
EPC615Mu61 | Bcl2相关髓细胞白血病序列1(MCL1)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAC615Mu01 | Bcl2相关髓细胞白血病序列1(MCL1)多克隆抗体 | WB; IHC; ICC/IF;FCM |
PAC615Mu02 | Bcl2相关髓细胞白血病序列1(MCL1)多克隆抗体 | WB; IHC; ICC; IP. |
SEC615Mu | Bcl2相关髓细胞白血病序列1(MCL1)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMC615Mu | Bcl2相关髓细胞白血病序列1(MCL1)等多因子检测试剂盒(流式荧光发光法) | FLIA Kit for Antigen Detection. |
参考文献
杂志 | 参考文献 |
Cancers | Rationale for a Combination Therapy Consisting of MCL1-and MEK-Inhibitors in Acute Myeloid Leukemia [Pubmed: 31718075] |
ACTA NEUROPATHOLOGICA COMMUNICATIONS | Restoration of miR-193a expression is tumor-suppressive in MYC amplified Group 3 medulloblastoma [Pubmed: 32410663] |
Cancers (Basel) | BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia. Cancers 2021, 13, 581 [33540760] |
留言咨询